---
title: "Kiniksa Pharmaceuticals International, plc (KNSA.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/KNSA.US.md"
symbol: "KNSA.US"
name: "Kiniksa Pharmaceuticals International, plc"
industry: "Biotechnology"
datetime: "2026-05-20T03:06:43.912Z"
locales:
  - [en](https://longbridge.com/en/quote/KNSA.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/KNSA.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/KNSA.US.md)
---

# Kiniksa Pharmaceuticals International, plc (KNSA.US)

## Company Overview

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.kiniksa.com](https://www.kiniksa.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: A
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:13.000Z

**Overall: A (0.17)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 1 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: A

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 56.71% |  |
| Net Profit YoY | 531.02% |  |
| P/B Ratio | 6.81 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 4122416376.00 |  |
| Revenue | 754045000.00 |  |

#### Multi Score Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 13.74% | B |
| Profit Margin | 9.69% | B |
| Gross Margin | 55.02% | B |
| Revenue YoY | 56.71% | A |
| Net Profit YoY | 531.02% | A |
| Total Assets YoY | 37.70% | A |
| Net Assets YoY | 32.39% | A |
| Cash Flow Margin | 227.03% | B |
| OCF YoY | 56.71% | A |
| Turnover | 1.06 | A |
| Gearing Ratio | 26.61% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Kiniksa Pharmaceuticals International, plc",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "56.71%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "531.02%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "6.81",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "4122416376.00",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "754045000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "A",
      "indicators": [
        {
          "name": "ROE",
          "value": "13.74%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "9.69%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "55.02%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "56.71%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "531.02%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "37.70%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "32.39%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "227.03%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "56.71%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "1.06",
          "rating": "A"
        },
        {
          "name": "Gearing Ratio",
          "value": "26.61%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 56.11 | 52/386 | 521.38 | 88.27 | 60.99 |
| PB | 6.77 | 361/386 | 6.21 | 5.80 | 4.81 |
| PS (TTM) | 5.44 | 116/386 | 5.43 | 5.16 | 4.51 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-11T04:00:00.000Z

Total Analysts: **8**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 7 | 88% |
| Overweight | 1 | 13% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 53.34 |
| Highest Target | 72.00 |
| Lowest Target | 57.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/KNSA.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/KNSA.US/norm.md)
- [Related News](https://longbridge.com/en/quote/KNSA.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/KNSA.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**